We are going to increase our production and, by the end of the year, we think we will have 2.5 billion doses of the vaccine produced”, said Kathrin Jansen, who participated, by videoconference, in the Science 2021 meeting, promoted by the Foundation for Science and Technology , in collaboration with the National Agency for Scientific and Technological Culture - Ciência Viva. According to the scientist, who led the development of the Pfizer/BioNTech vaccine, the company will work on new vaccine formulas that allow for easier storage, as well as the reinforcement of the immunisation provided by the drug. “We are going to explore the strengthening of immunization, because we do not know when the effectiveness [of the vaccine] may be reduced and we want to be prepared”, said Kathrin Jansen, noting that, “even before the World Health Organization declares the pandemic, already it was clear to some that the best way to deal [with Covid-19] was with the development of a vaccine.”

According to the scientist, the Pfizer/BioNTech vaccine “took just nine months” to receive authorization for emergency use in the United States and, until the last week, the drug has already received authorization in more than 80 countries and more have already been delivered with 800 million doses globally. The vaccine developed by the American pharmaceutical Pfizer and the German laboratory BioNTech, which is administered in two doses, uses a new technology in the area of ​​vaccines, based on a molecule called messenger RNA (mRNA).